King Luther Capital Management Corp Sells 9,274 Shares of Johnson & Johnson $JNJ

King Luther Capital Management Corp trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 839,340 shares of the company’s stock after selling 9,274 shares during the period. Johnson & Johnson comprises 0.9% of King Luther Capital Management Corp’s holdings, making the stock its 26th biggest holding. King Luther Capital Management Corp’s holdings in Johnson & Johnson were worth $222,207,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Banyan Capital Management Inc. bought a new stake in shares of Johnson & Johnson in the third quarter valued at about $703,000. CFM Wealth Partners LLC grew its holdings in Johnson & Johnson by 3.9% during the 3rd quarter. CFM Wealth Partners LLC now owns 2,127 shares of the company’s stock worth $563,000 after acquiring an additional 80 shares in the last quarter. Smith Partners Wealth Management LLC grew its holdings in Johnson & Johnson by 28.0% during the 3rd quarter. Smith Partners Wealth Management LLC now owns 1,963 shares of the company’s stock worth $520,000 after acquiring an additional 430 shares in the last quarter. Maryland State Retirement & Pension System grew its holdings in Johnson & Johnson by 13.9% during the 3rd quarter. Maryland State Retirement & Pension System now owns 147,725 shares of the company’s stock worth $39,109,000 after acquiring an additional 18,023 shares in the last quarter. Finally, Advisor Resource Council increased its position in Johnson & Johnson by 4.0% during the 3rd quarter. Advisor Resource Council now owns 4,798 shares of the company’s stock valued at $1,214,000 after purchasing an additional 186 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $280.52 on Thursday. Johnson & Johnson has a fifty-two week low of $193.07 and a fifty-two week high of $283.25. The company has a market cap of $675.29 billion, a PE ratio of 42.50, a P/E/G ratio of 2.78 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The business has a 50-day simple moving average of $266.67 and a two-hundred day simple moving average of $249.23.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Key Johnson & Johnson News

These are some of the JNJ news items that stood out recently:

• Positive Sentiment: J&J reported that a second pivotal Phase 3 trial of CAPLYTA met its primary and key secondary endpoints for bipolar I mania, with symptom improvement seen as early as Day 3. The two positive trials support a planned U.S. FDA submission, adding a potential growth opportunity. Reuters article
• Positive Sentiment: Oncology sales rose 16.8% to $22 billion in the first nine months of 2026, supported by established medicines and new launches. Another article points to recent launches and business changes as potential support for double-digit growth by 2030, though that outlook is prospective. Oncology sales article
• Negative Sentiment: A Massachusetts jury awarded $3.3 million, including interest, to a family in a mesothelioma case tied to J&J talc-based baby powder. The award adds to the company’s ongoing talc litigation exposure. Verdict announcement

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on JNJ. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Tuesday, September 29th. Bank of America reiterated a “neutral” rating and set a $278.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. Finally, Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $275.92.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.